TITLE

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

AUTHOR(S)
Atkinson, W.; Sheldon, T. A.; Shaath, N.; Whorwell, P. J.
PUB. DATE
October 2004
SOURCE
Gut;Oct2004, Vol. 53 Issue 10, p1459
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Patients with irritable bowel syndrome (IBS) often feel they have some form of dietary intolerance and frequently try exclusion diets. Tests attempting to predict food sensitivity in IBS have been disappointing but none has utilised IgG antibodies. Aims: To assess the therapeutic potential of dietary elimination based on the presence of IgG antibodies to food. Patients: A total of 150 outpatients with IBS were randomised to receive, for three months, either a diet excluding all foods to which they had raised IgG antibodies (enzyme linked immunosorbant assay test) or a sham diet excluding the same number of foods but not those to which they had antibodies. Methods: Primary outcome measures were change in IBS symptom severity and global rating scores. Non-colonic symptomatology, quality of life, and anxiety/depression were secondary outcomes. Intention to treat analysis was undertaken using a generalised linear model. Results:After 12 weeks, the true diet resulted in a 10% greater reduction in symptom score than the sham diet (mean difference 39 (95% confidence intervals (CI) 5-72); p = 0.024) with this value increasing to 26% in fully compliant patients (difference 98 (95% CI 52-144); p<0.001). Global rating also significantly improved in the true diet group as a whole (p = 0.048, NNT = 9) and even more in compliant patients (p = 0.006, NNT = 2.5). All other outcomes showed trends favouring the true diet. Relaxing the diet led to a 24% greater deterioration in symptoms in those on the true diet (difference 52 (95% CI 18-88); p = 0.003). Conclusion: Food elimination based on IgG antibodies may be effective in reducing IBS symptoms and is worthy of further biomedical research.
ACCESSION #
14674391

 

Related Articles

  • Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome. Shah, Eric; Pimentel, Mark // Journal of Neurogastroenterology & Motility;Apr2014, Vol. 20 Issue 2, p163 

    Ongoing efforts to improve clinical trial design in irritable bowel syndrome have been hindered by high placebo response rates and ineffective outcome measures. We assessed established strategies to minimize placebo effect as well as the various approaches to placebo effect which can affect...

  • SSRIs provide modest benefit in selected patients with IBS.  // BMJ: British Medical Journal (International Edition);11/13/2004, Vol. 329 Issue 7475, p1112 

    Presents a question and answer column concerning the use of selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Synopsis of the use of the drugs and a randomised trial to see if the medications had value; Finding that a there was a small benefit to using...

  • Linzess: A Novel Treatment Option for Constipation Associated with Irritable Bowel Syndrome. Goodman, Alice // American Health & Drug Benefits;Apr2013, Vol. 6 Issue 3, p57 

    The article discusses the Food and Drug Administration (FDA) approval for linzess in December 2012 as a new option for the treatment of constipation due to irritable bowel syndrome (IBS). Topics include information about IBS, its symptoms and causes, the FDA-approved linaclotide as a guanylate...

  • Patient reported outcome measures in trials. Garratt, Andrew // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/17/2009, p119 

    The article discusses patient reported outcomes measures in clinical trials. Measures that are specific to a disease or population and those that can be applied across populations are discussed. The short form 36 item (SF-36) health survey questionnaire is described. The authors explain that the...

  • Sepsis: needs for defining severity. Gattinoni, Luciano; Ranieri, V.; Pesenti, Antonio // Intensive Care Medicine;Mar2015, Vol. 41 Issue 3, p551 

    The article focuses on five clinical trials published by "The New England Journal of Medicine," testing different interventions in patients with severe sepsis. Topics discussed include the outcome difference between trials conducted in Europe compared to the ones performed in the Anglo-Saxon...

  • Where Does Hypnotherapy Stand in the Management of Irritable Bowel Syndrome? A Systematic Review. Gholamrezaei, Ali; Ardestani, Samaneh Khanpour; Emami, Mohammad Hasan // Journal of Alternative & Complementary Medicine;Jul/Aug2006, Vol. 12 Issue 6, p517 

    Background: Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause. Despite its prevalence, there remains a significant lack of efficient medical treatment for IBS to date. However,...

  • Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome. LOVE, BRYAN L.; JOHNSON, AUDREY; SMITH, LISA S. // American Journal of Health-System Pharmacy;7/1/2014, Vol. 71 Issue 13, p1081 

    Purpose. The pharmacology, pharmacokinetics, and clinical efficacy and safety of linaclotide in the management of chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C) are reviewed. Summary. Linaclotide (Linzess, Forest Pharmaceuticals) is a 14-amino acid...

  • Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Norquist, Josephine; Girman, Cynthia; Fehnel, Sheri; DeMuro-Mercon, Carla; Santanello, Nancy // Quality of Life Research;Aug2012, Vol. 21 Issue 6, p1013 

    Purpose: Understand the choice of recall period for PRO measures based on intended use, characteristics of the disease, treatment, and attributes of studies. Methods: Current practice and considerations were reviewed within several disease areas (overactive bladder, menopausal hot flashes,...

  • Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Bijkerk, C.J.; de Wit, N.J.; Muris, J.W.M.; Jones, R.H.; Knottnerus, J.A.; Hoes, A.W. // American Journal of Gastroenterology;Jan2003, Vol. 98 Issue 1, p122 

    : ObjectivesAlthough there is growing interest in irritable bowel syndrome (IBS) research, there is as yet no consensus regarding the preferred outcome measure. We aimed to evaluate and to compare the validity and appropriateness of available IBS outcome measures.: MethodsIBS symptom and IBS...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics